Sichenzia Ross Ference LLP Represents Beyond Air in $50 Million At-The-Market Offering
Press Release – New York, NY – April 23, 2020 – Sichenzia Ross Ference LLP announced today that it represented Beyond Air, Inc. (NASDAQ: “XAIR”), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, in an At-The-Market Offering (“ATM”) under which the Company may offer and sell from time to time shares of its common stock having an aggregate offering price of up to $50,000,000.
SunTrust Robinson Humphrey, Inc. and Oppenheimer & Co. acted as agents for the ATM.
The shares were registered on the Company’s Registration Statement on Form S-3 (File No. 333-231416) filed with the SEC on May 13, 2019 and declared effective on July 2, 2019, and the prospectus supplement relating to the ATM filed with the SEC on April 2, 2020.
The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia and Avital Perlman and associate Jacob Tabman.